Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Azithromycin, ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development

Turner, Mark A., Jacqz-Aigrain, Evelyne and Kotecha, Sailesh 2011. Azithromycin, ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development. Archives of Disease in Childhood 97 (6) , pp. 573-577. 10.1136/adc.2010.195180

Full text not available from this repository.

Abstract

Chronic lung disease of prematurity (CLD) remains a major cause of morbidity and mortality in preterm infants. Ureaplasma has received intermittent attention over the last two decades as a possible contributory factor. In addition, pulmonary inflammation is associated with the development of CLD. The macrolide azithromycin provides an attractive option to determine if it can decrease the development of CLD as it has both anti-inflammatory and anti-infective properties. In this article, the authors review the evidence for the role of Ureaplasma in the development of CLD and the obstacles faced in the development of a drug before it reaches clinical practice.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services
Publisher: BMJ Publishing Group
ISSN: 0003-9888
Last Modified: 04 Jun 2017 03:50
URI: http://orca-mwe.cf.ac.uk/id/eprint/27778

Citation Data

Cited 10 times in Google Scholar. View in Google Scholar

Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item